drugset / Trial / NCT00040664
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a 48-week study to collect additional information on the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen (course of therapy) including FDA approved HIV drugs in HIV-infected patients 2 - 18 years old.
Timeline
- Start
- 2002-07
- Primary completion
- 2008-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fosamprenavir | Small molecule | 50 mg/ml | Oral |
| Subject | Fosamprenavir | Small molecule | 700 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 80 mg/ml | Oral |
| Subject | Ritonavir | Other / unclassified | 100 mg | Oral |